EA201270567A1 - Противомикробные соединения и способы их получения и применения - Google Patents

Противомикробные соединения и способы их получения и применения

Info

Publication number
EA201270567A1
EA201270567A1 EA201270567A EA201270567A EA201270567A1 EA 201270567 A1 EA201270567 A1 EA 201270567A1 EA 201270567 A EA201270567 A EA 201270567A EA 201270567 A EA201270567 A EA 201270567A EA 201270567 A1 EA201270567 A1 EA 201270567A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
production
application
antimicrobial compounds
compounds
Prior art date
Application number
EA201270567A
Other languages
English (en)
Other versions
EA023350B1 (ru
Inventor
Эрин М. Даффи
Ашоке Бхаттачарджи
Хардвин О'Доуд
Марко Девиво
Яньмин Ду
Сандра Сиништаж
Юаньцин Тан
Брайан Т. Вимберли
Original Assignee
Риб-Экс Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Риб-Экс Фармасьютикалз, Инк. filed Critical Риб-Экс Фармасьютикалз, Инк.
Publication of EA201270567A1 publication Critical patent/EA201270567A1/ru
Publication of EA023350B1 publication Critical patent/EA023350B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6862—Stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится в целом к области противомикробных соединений и к способам их получения и применения. Эти соединения могут быть использованы для лечения, профилактики и уменьшения риска микробных инфекций у человека и животных.
EA201270567A 2009-10-16 2010-10-15 Противомикробные соединения, способы их получения и применение EA023350B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25247809P 2009-10-16 2009-10-16
US31428710P 2010-03-16 2010-03-16
US35820110P 2010-06-24 2010-06-24
PCT/US2010/052928 WO2011047323A2 (en) 2009-10-16 2010-10-15 Antimicrobial compounds and methods of making and using the same

Publications (2)

Publication Number Publication Date
EA201270567A1 true EA201270567A1 (ru) 2012-12-28
EA023350B1 EA023350B1 (ru) 2016-05-31

Family

ID=44343890

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270567A EA023350B1 (ru) 2009-10-16 2010-10-15 Противомикробные соединения, способы их получения и применение

Country Status (14)

Country Link
US (3) US9216979B2 (ru)
EP (1) EP2488502A4 (ru)
JP (1) JP2013508299A (ru)
KR (1) KR20180069098A (ru)
CN (1) CN102725274A (ru)
AU (3) AU2010306650B2 (ru)
BR (1) BR112012008795A2 (ru)
CA (1) CA2777741A1 (ru)
EA (1) EA023350B1 (ru)
IL (1) IL219135A0 (ru)
MX (2) MX339000B (ru)
MY (1) MY176900A (ru)
NZ (1) NZ599290A (ru)
WO (1) WO2011047323A2 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180051676A (ko) 2009-10-16 2018-05-16 멜린타 테라퓨틱스, 인크. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
MX339000B (es) * 2009-10-16 2016-05-09 Melinta Therapeutics Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
WO2012097274A1 (en) 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporation Process of making gyrase and topoisomerase iv inhibitors
RU2625305C2 (ru) 2011-01-14 2017-07-13 Сперо Тринем, Инк. Твердые формы ингибитора гиразы (r)-1-этил-3-[6-фтор-5[2-(1-гидрокси-1-метил-этил) пиримидин-5-ил]-7-(тетрагидрофуран-2-ил)-1н-бензимидазол-2-ил] мочевины
KR101897950B1 (ko) 2011-01-14 2018-09-12 스페로 트리넴, 인코포레이티드 자이라제 억제제 （ｒ）­１­에틸­３­［５­［２­｛１­하이드록시­１­메틸­에틸｝피리미딘­５­일］­７­（테트라하이드로푸란­２­일｝­１ｈ­벤즈이미다졸­2­일］우레아의 고체 형태
AU2012205415B2 (en) 2011-01-14 2017-02-02 Spero Therapeutics, Inc. Pyrimidine gyrase and topoisomerase IV inhibitors
TWI554515B (zh) 2011-06-20 2016-10-21 維泰克斯製藥公司 旋轉酶（ｇｙｒａｓｅ）及拓樸異構酶抑制劑之磷酸酯
US9018216B2 (en) 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
CA2923214A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CA2923179A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
WO2016020373A1 (en) * 2014-08-06 2016-02-11 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
EP3268370A4 (en) 2015-03-11 2018-08-22 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3287443B1 (en) 2015-04-24 2021-10-27 Shionogi & Co., Ltd 6-membered heterocyclic derivative and pharmaceutical composition comprising same
CN110312722A (zh) * 2016-05-06 2019-10-08 生物验证系统股份公司 抗微生物剂及其制备和使用方法
WO2018074390A1 (ja) 2016-10-17 2018-04-26 塩野義製薬株式会社 二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
WO2019013790A1 (en) 2017-07-12 2019-01-17 Curza Global, Llc ANTIMICROBIAL COMPOUNDS AND USES THEREOF
WO2019013789A1 (en) 2017-07-12 2019-01-17 Curza Global, Llc ANTIMICROBIAL COMPOUNDS
WO2020150385A1 (en) 2019-01-16 2020-07-23 Curza Global, Llc Antimicrobial compounds and methods
AU2020209167A1 (en) 2019-01-16 2021-08-12 Curza Global, Llc Antimicrobial compounds and methods
EP4085910A1 (en) * 2021-05-05 2022-11-09 4Living Biotech Use of a compound such as plerixafor for treating a viral pulmonary disease
TW202313065A (zh) 2021-05-28 2023-04-01 美商季卡尼醫療公司 用於治療遺傳疾病之化合物
WO2023250513A1 (en) 2022-06-24 2023-12-28 Zikani Therapeutics, Inc. 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation
WO2024036254A2 (en) 2022-08-11 2024-02-15 Zikani Therapeutics, Inc. Synthetic processes and intermediates for preparing therapeutic azaketolides
WO2024049994A1 (en) 2022-09-01 2024-03-07 Zikani Therapeutics, Inc. Treatment of familial adenomatous polyopsis using a 13-membered macrolide

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624731A (en) * 1953-01-06 S-phenylpyrimidkn e x derivativesx
US3980781A (en) * 1966-03-31 1976-09-14 Imperial Chemical Industries Limited Fungicidal composition and method containing 2-amino-pyrimidines
US4361557A (en) 1980-01-28 1982-11-30 Schering Corporation 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor
EP0067610A1 (en) 1981-06-16 1982-12-22 Beecham Group Plc Penicillins, a process for their preparation and compositions containing them
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5332835A (en) 1984-02-03 1994-07-26 Zambon S.P.A. Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds and new oxazoline compounds useful in this process
JPS6191184A (ja) * 1984-10-08 1986-05-09 Morishita Seiyaku Kk ２−アニリノ−５−（１ｈ−テトラゾ−ル−５−イル）ピリミジン−４（３ｈ）−オン誘導体
JP2873340B2 (ja) 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質ｔａｎ―１０５７，その製造法および用途
JP2991382B2 (ja) 1990-07-18 1999-12-20 大日本製薬株式会社 縮合三環式化合物およびその塩
US5208141A (en) 1990-10-09 1993-05-04 Konica Corporation Silver halide color photographic light-sensitive material
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US6451968B1 (en) 1991-05-24 2002-09-17 Isis Pharmaceuticals, Inc. Peptide nucleic acids
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5646163A (en) 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
WO1994026722A1 (en) 1993-05-12 1994-11-24 E.I. Du Pont De Nemours And Company Fungicidal fused bicyclic pyrimidinones
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
TW424090B (en) * 1995-08-18 2001-03-01 Nat Science Council Pyrimidines as folate antimetabolites with selective activity against human brain cancer
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US7282327B2 (en) * 1996-01-23 2007-10-16 Affymetrix, Inc. Nucleic acid labeling compounds
GB9708611D0 (en) 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
WO1999007685A1 (en) 1997-08-07 1999-02-18 Research Corporation Technologies, Inc. Antibiotic for methicillin resistant bacteria
WO1999024452A2 (en) 1997-11-07 1999-05-20 Isis Pharmaceuticals, Inc. Pyrimidine derivatives for labeled binding partners
US6028183A (en) 1997-11-07 2000-02-22 Gilead Sciences, Inc. Pyrimidine derivatives and oligonucleotides containing same
DE19838998A1 (de) * 1998-08-27 2000-03-09 Bayer Ag Neue Naturstoffderivate
WO2001007027A2 (en) * 1999-07-22 2001-02-01 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives for the treatment of viral diseases
SE9903894D0 (sv) * 1999-10-28 1999-10-28 New Pharma Research Ab Novel compounds
EP1113008A1 (en) 1999-12-29 2001-07-04 Pfizer Products Inc. 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents
KR100358083B1 (ko) 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
DE10061542A1 (de) * 2000-12-11 2002-06-13 Bayer Ag Alkanoylamino-pyrimidine
DE10061538A1 (de) 2000-12-11 2002-06-20 Bayer Ag Ureido-Dihydropyrimidinone
DE10061537A1 (de) 2000-12-11 2002-06-20 Bayer Ag beta-Alanin-Derivate
DE10061541A1 (de) 2000-12-11 2002-06-20 Bayer Ag Arylamino-Dihydropyrimidinone
PL363323A1 (en) 2000-12-14 2004-11-15 The Procter & Gamble Company Antimicrobial quinolones
US6900215B2 (en) 2000-12-15 2005-05-31 Merck Sharp & Dohme Ltd. Imidazo-pyrimidine derivatives as ligands for gaba receptors
WO2002061110A2 (en) 2001-01-29 2002-08-08 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
WO2002097134A2 (en) 2001-05-25 2002-12-05 Isis Pharmaceuticals, Inc. Modified peptide nucleic acid
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20030158403A1 (en) 2001-07-03 2003-08-21 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
DE10133277A1 (de) 2001-07-09 2003-01-23 Bayer Ag ß-Alanin-Derivate
DE10141271A1 (de) 2001-08-23 2003-03-06 Bayer Ag Neue Tetrahydro-1,3,5-triazin-2-on-Derivate und ihre Verwendung
DE10208256A1 (de) 2002-02-26 2003-09-04 Bayer Ag Piperidinouracile
TW200406372A (en) 2002-03-08 2004-05-01 Schering Plough Ltd Novel florfenicol-type antibiotics
AU2003225705A1 (en) 2003-03-07 2004-09-30 Ribapharm Inc. Cytidine analogs and methods of use
JP5147237B2 (ja) 2003-08-12 2013-02-20 アキリオン ファーマシューティカルズ，インコーポレーテッド 抗感染剤としてのイソチアゾロキノロン類および関連化合物
CA2536887C (en) 2003-08-26 2012-03-06 Teijin Pharma Limited Pyrrolopyrimidinone derivatives
TW200524880A (en) * 2003-10-21 2005-08-01 Sankyo Co Pyrimidine compounds
AU2006272571B2 (en) 2005-07-27 2012-03-08 Achillion Pharmaceuticals, Inc. 8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents
EP1951680A4 (en) 2005-11-15 2011-08-10 Astrazeneca Ab NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE
NZ544187A (en) 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP2007270087A (ja) * 2006-03-31 2007-10-18 Fujifilm Corp 硬化性組成物、インク組成物、インクジェット記録方法、印刷物、平版印刷版の製造方法、及び平版印刷版
ATE496766T1 (de) 2006-03-03 2011-02-15 Fujifilm Corp Härtbare zusammensetzung, tintenzusammensetzung, tintenstrahlaufzeichnungsverfahren und flachdruckplatte
MX2009000102A (es) 2006-07-03 2009-03-02 Sk Chemicals Co Ltd Sales de derivados de pirrolopirimidinona y proceso para prepararlas.
KR20080003599A (ko) 2006-07-03 2008-01-08 에스케이케미칼주식회사 피롤로피리미디논 유도체의 겐티세이트 염 및 이의제조방법
US20100112561A1 (en) 2006-08-25 2010-05-06 Stefan Lutz Fluorescent nucleoside analogues
SI2057165T1 (sl) 2006-09-07 2011-07-29 Ind Res Ltd Gracefield Res Ct Acikliäśni aminski zaviralci nukleozidnih fosforilaz in hidrolaz
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
WO2008106204A1 (en) 2007-02-28 2008-09-04 Rib-X-Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
US20080221093A1 (en) * 2007-03-07 2008-09-11 Christian Gege Metalloprotease inhibitors containing a heterocyclic moiety
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
WO2008150406A1 (en) 2007-05-30 2008-12-11 Schering-Plough Ltd. A process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol
CN107021895A (zh) 2007-06-12 2017-08-08 尔察祯有限公司 抗菌剂
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
KR20090098710A (ko) 2008-03-14 2009-09-17 주식회사 씨티아이바이오 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체
US20100190747A1 (en) 2009-01-27 2010-07-29 Hideo Suzuki Fused ring compound and use thereof
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
KR20180051676A (ko) 2009-10-16 2018-05-16 멜린타 테라퓨틱스, 인크. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
CN108456211A (zh) 2009-10-16 2018-08-28 梅琳塔治疗公司 抗微生物化合物和其制备和使用方法
MX339000B (es) * 2009-10-16 2016-05-09 Melinta Therapeutics Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
JP6267863B2 (ja) 2009-10-16 2018-01-24 メリンタ セラピューティクス，インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
CA2829993A1 (en) 2011-03-15 2012-09-20 Rib-X Pharmaceuticals, Inc. Antimicrobial agents
PT2697229T (pt) 2011-04-15 2018-04-13 Melinta Therapeutics Inc Compostos antimicrobianos e seus métodos de fabrico e de utilização
CA2923214A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CA2923179A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same

Also Published As

Publication number Publication date
WO2011047323A3 (en) 2011-08-18
CA2777741A1 (en) 2011-04-21
KR20180069098A (ko) 2018-06-22
NZ599290A (en) 2014-10-31
MX358697B (es) 2018-08-31
WO2011047323A2 (en) 2011-04-21
EA023350B1 (ru) 2016-05-31
MX339000B (es) 2016-05-09
IL219135A0 (en) 2012-06-28
JP2013508299A (ja) 2013-03-07
AU2010306650B2 (en) 2016-10-13
BR112012008795A2 (pt) 2020-09-24
US20160031828A1 (en) 2016-02-04
MY176900A (en) 2020-08-26
MX2012004342A (es) 2012-10-03
US9216979B2 (en) 2015-12-22
EP2488502A2 (en) 2012-08-22
US20130090326A1 (en) 2013-04-11
US20180334439A1 (en) 2018-11-22
AU2010306650A1 (en) 2012-05-03
AU2018202065A1 (en) 2018-04-19
EP2488502A4 (en) 2013-05-15
AU2016231568A1 (en) 2016-10-20
US9845297B2 (en) 2017-12-19
CN102725274A (zh) 2012-10-10

Similar Documents

Publication Publication Date Title
EA201270566A1 (ru) Противомикробные соединения и способы их получения и применения
EA201270567A1 (ru) Противомикробные соединения и способы их получения и применения
EA201391536A1 (ru) Противомикробные соединения и способы их получения и применения
EA201792006A1 (ru) Антимикробные соединения и способы их получения и их применение
EA201270568A1 (ru) Антимикробные композиции и способы их получения и применения
EA201390274A1 (ru) Борсодержащие малые молекулы
PH12016500453A1 (en) Antimicrobial compounds and methods of making and using the same
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201270254A1 (ru) Производные 5-фторпиримидинона
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
MX351670B (es) Bacteria bacillus para uso en tratar y prevenir infecciones en animales acuaticos.
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
GEP201606580B (en) Topical compositions comprising fipronil and permethrin and methods of use
EA201500913A1 (ru) Противомикробные соединения и способы их получения и применения
EA201270253A1 (ru) Производные n1-ацил-5-фторпиримидинона
UA107346C2 (en) Use of nifuratel to treat infections caused by atopobium species
BRPI1006875A2 (pt) composição farmacêutica, bactérias, uso de bactérias vivas, e, métodos para tratar um animal.
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
IN2013MU03216A (ru)
WO2015035234A3 (en) Anti-microbial compounds and compositions
EA201270547A1 (ru) Фармацевтическая композиция
AU2014353885A8 (en) Prevention and treatment of toxicosis
NZ713741A (en) Antimicrobial compounds and methods of making and using the same
EA201390764A1 (ru) Фармацевтические композиции

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU